



Strategic MedComms Forum 2011:
Trust and Transparency – Myth and Reality
#medcomms

London, 14 September 2011



Sharing data. Opening the Pandora's Box?

London, 14 September 2011

Panel Members

- **Doug Altman, EQUATOR**
- **Lorna Fay, Pfizer**
- **Iain Hrynaszkiewicz, BioMed Central**
- **Adam Jacobs, Dianthus Medical**
- **Tatjana Poplazarova, GSK Biologicals**

*I keep six honest serving-men
(They taught me all I knew);
Their names are What and Why
and When
And How and Where and Who.*

Rudyard Kipling

What, why, when?

- **What data should we (and do we) share?**
 - summary data or individual level data?
 - statistical code?
 - all trials, phase II onwards, pre-clinical?
- **Why share data?**
 - does it benefit us?
 - does it benefit others?
- **When do we share data?**
 - same time as publication or after delay?

How, where, who?

- **How do we share data?**
 - precautions for protecting patient privacy?
 - data standards?
- **Where can we share data?**
 - what should role of journals be?
 - specialised data repositories?
- **Who owns the data?**
 - what are the IP implications of data sharing?



Questions & Discussion

London, 14 September 2011